By switching from one cellular identity to another, lung cancer cells can evade targeted therapies. MSK scientists are trying to stop that from happening.

Stem-like cells that make up only a tiny fraction of the total cells in a lung tumor could be the key to stopping the disease’s deadly spread, say researchers at Memorial Sloan Kettering.

Lung cancer has an uncanny ability to change its identity to resist drugs. Researchers are learning what drives these changes.

MSK today announced a $20 million gift from the Ge Li & Ning Zhao Family Foundation to support lung cancer research and the development of new therapies to treat this disease.

Researchers discover that a subset of lung adenocarcinomas are aggressive because of mutations that allow them to block ferroptosis, a type of cell death.

Chief of the Melanoma Service Michael Postow, MD, Medical Oncologist Nitya Raj, MD, and Assistant Attending Triparna Sen, PhD were included on this year’s list.

During the upcoming ASCO Virtual Scientific Program, MSK Chief of Thoracic Oncology Service Charles M. Rudin, MD, PhD, will present a study that found pembrolizumab addition to first-line chemotherapy significantly improved progression-free survival for patients with small cell lung cancer (SCLC).

An epigenetic mechanism may make small cell lung cancer vulnerable to a new kind of attack.